Welcome to our dedicated page for DAMORA THERAPEUT SEC filings (Ticker: DMRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on DAMORA THERAPEUT's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into DAMORA THERAPEUT's regulatory disclosures and financial reporting.
Damora Therapeutics is repositioning as a hematology-focused biopharmaceutical company built around antibodies targeting mutant calreticulin (mutCALR) in myeloproliferative neoplasms such as essential thrombocythemia and myelofibrosis. Its lead candidate, DMR-001, is a monoclonal antibody engineered for higher potency against Type 1 and Type 2 mutCALR and longer half-life than a reference mutCALR antibody with the same mechanism as INCA033989, aiming to enable convenient subcutaneous dosing.
The company plans to file IND or CTA submissions for DMR-001 in mid-2026 and start a Phase 1 trial in ET and MF, with proof‑of‑concept readouts expected beginning mid‑2027. Follow-on candidates DMR-002 and DMR-003 are designed to broaden coverage across the mutCALR disease spectrum, with planned regulatory filings in the second half of 2026 and in 2027, respectively.
Damora acquired private “Pre‑Acquisition Damora” via a stock‑for‑stock asset acquisition and assumed an extensive option and research collaboration with Paragon Therapeutics, including options on DMR‑001, DMR‑002 and DMR‑003. To fund this strategy, it completed a $285 million PIPE in November 2025 and a follow‑on underwritten offering raising approximately $297.3 million in net proceeds in February 2026, alongside a new $150.0 million at‑the‑market program.